BLUTH BIO INDUSTRIES
  • BLUTH BIO INDUSTRIES
  • TEAM
  • Technologies
    • Therapeutics >
      • SOPHOROLIPIDS FOR THE TREATMENT OF ASTHMA
      • RECIPROCAL SERUM/PLASMA EXCHANGE FOR TREATMENT OF CANCER
      • PANCREATITIS ASSOCIATED PROTEINS (PAP) FOR TREATMENT OF PANCREATITIS
      • REGENERATION (REG) PROTEINS FOR THE TREATMENT OF DIABETES
      • STEM CELL THERAPY FOR DIABETES
      • IMMUNEX – RECOMBINANT HUMAN IgGFc FOR THE TREATMENT OF AUTOIMMUNE DISEASE
    • Diagnostics >
      • BIOMARKER (BLOOD TEST) DEVELOPMENT AND COMMERCIALIZATION PLATFORM
      • BLOOD TEST FOR DETECTION OF PANCREATIC CANCER
    • Devices >
      • Pheonix TM needle
      • Scratchless Scope TM
      • Bottle Buddy TM
    • Services >
      • Bluth Bio Consulting LLC
      • Publication and Grant Review Services
      • Business of Healthcare
      • Medical Martial Arts
  • News
  • SELECT PUBLICATIONS
  • CONTACT
  • Relationships
REGENERATION (REG) PROTEINS FOR THE TREATMENT OF DIABETES

Background: Diabetes is a condition which is proposed to affect upwards of 30% or greater of the US population by the year 2020 imposing an extreme economic burden on the healthcare system.

Diabetes market:

Ø      Diabetes affects 285 million people worldwide.

Ø      7 million people develop diabetes each year

Ø      This number is expected to hit 438 million by 2030

Ø      The incidence is increasing due to the aging population, increasing rates of obesity and sedentary lifestyle

Ø      Considerable costs for healthcare system and loss of work

Ø      People with diabetes incur medical costs that are two to three times higher than those without diabetes. A person with diabetes can face direct costs for medication and supplies ranging from $1,000 to $15,000 a year.

Ø      By 2020, it’s estimated that diabetes will cost select healthcare system $16.9 billion a year.

Preclinical data: We have demonstrated that regeneration (Reg) proteins is able to improve diabetes in laboratory animals by regulating their glucose tolerance. We have designed a recombinant form of this protein for future application to clinical trials.

 IP: REG protein for use in diabetes - Patent application filed.

References:

Bluth MH, Patel SA, Wu H, Fan Z, Okamato H, Dieckgraefe B, Zenilman ME. Pancreatic

regenerating protein (reg I) and reg I receptor mRNA are upregulated in rat pancreas after induction of acute pancreatitis. World Journal of Gastroenterology 2006;12:4511-4516.

Bluth MH, Mueller CM, Pierre J, Callender G, Kandil E, Viterbo D, Fu SL, Sugawara A,

Takasawa S, Okamoto H, Zenilman ME. Pancreatic reg I in chronic pancreatitis and aging: Implications for new therapeutic approaches to diabetes. Pancreas 2008;37:386-395.


Powered by Create your own unique website with customizable templates.